Baillie Gifford & CO Denali Therapeutics Inc. Call Options Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DNLI
# of Institutions
252Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$202 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$181 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$101 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$96.2 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA5.66MShares$87 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.06B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...